Prognostic value of markers of aggressiveness of urinary bladder tumours evaluated by immunohistochemistry

##plugins.themes.academic_pro.article.sidebar##

Published Jun 4, 2014
Download
pdf
Vol. 92 No. 3 (2014): Issue Mar 2014

##plugins.themes.academic_pro.article.main##

A. Chaabane
I. M'Sakni
M. Yahia
F. Bougrine
B. Laabidi
R. Khiari
S. Ghozzi
N. Berraies
A. Bouziani

Abstract

Background: The study of some immunohistochemical markers provides an objective and reproducible prognostic evaluation of urinary bladder tumour.

aims: study the expression of the following immunohistochemical markers in Tumours of the bladder: Proliferating Cell Nuclear Antigen (PCNA), Ki67 antigen (MIB1), the C-erbB2 proto- antigene, the tumor suppressor gene p53, the receptor for epidermal growth factor (EGF-R), the apoptosis suppressor gene bcl2, the carcinoembryonic antigen (CEA) and epithelial membrane antigen (EMA).

methods: Study of retrospective series of 30 patients having tumours of the urinary bladder.

results: The expression of PCNA with a cut-off value of 14% is correlated with recurrence (P = 0.010). The expression of PCNA with a cut-off value of 1% is correlated with tumour stage (P = 0.003). The expression of MIB1 with a cut-off value of 47% is correlated with recurrence (P = 0.010). The expression of MIB1 with a cut-off value of 47% is correlated with the tumour progression in stage and\or in grade (P = 0.007). The expression of C-erbB2 with a cutoff value of 28% is correlated in the tumour grade (P = 0.007). The other antibodies didn’t demonstrate a prognostic value.

Conclusion: MIb1 and PCNA being correlated with recurrence, they can be useful with the decision of the rhythm of the endoscopy. The correlation of C-erbB2 with the tumour grade could serve to better graduating bladder tumours.

Keywords:

Urinary bladder tumour, immunohistochemistry, prognosis.

##plugins.themes.academic_pro.article.details##

References

  1. Uchida T, Minei S, Gao JP et al. Clinical significance of p53, MDM2 and bcl2 expression in transitional cell carcinoma of the bladder. Oncol Rep 2002; 9: 253-9.
  2. Eble JN, Sauter G, Epstein JI, Sesterhenn TA. World health organisation classification of tumours. Lyon: IARC Press 2004: 89-119.
  3. Maalej M, Mosbah AF. Cancérologie pratique- Cancers de la vessie. Tunis : Centre des publications universitaires 1999: 345- 53.
  4. Molinié V, lonchampt E ,Ouzana D, Lebret T. Tumeurs de vessie et marqueurs moléculaires. Ann Pathol 2003; 23: 306-31.
  5. Burchardt M, Burchardt T, Shabsigh A, et al. Current Concepts in Biomarker Technology for Bladder Cancers. In Clin Chem 2000 ; 46: 595-605.
  6. Gattegno B. Chopin D. Histoire naturelle des tumeurs superficielles de vessie. Prog Urol 2001; 11: 963- 90.
  7. Aveyard P, Adab P, Cheng K K, et al. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 2002; 90: 228-239.
  8. Ali-El-Dein B, Sarhan O, Hinev A, et al. Superficial bladder tumors: analysis of prognostic factors and construction of a predictive index. BJU Int 2003 ; 92: 393-399.
  9. Sebe P, Lebret T, Molinie V, et al. Tumeurs superficielles de vessie de grade G2 : récidive, progression, pronostic. Prog Urol 2003; 13: 608-612.
  10. Santos LL, Amaro T, Pereira SA, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial lowgrade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 2003; 29: 74-80.
  11. Bol MGW, Baak JPA, Van Diermen B, et al. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. Journal of clinical pathology 2003; 56: 447-52.
  12. Rodríguez-Alonso A, Pita-Fernández S, González-Carreró J. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 2002; 41: 182-9.
  13. Billerey C, Sibony M. Les tumeurs urothéliales dites« superficielles » de la vessie. Quelle classification en 2003 ? Ann Pathol 2003; 23: 21-33.
  14. Rey A, Lara PC, Redondo E, et al. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer 1997; 79: 2178-2185.
  15. Skopelitou A, Hadjiyannakis M, Dimopoulos D, et al. p53 and cjun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. Eur Urol 1997; 31: 464-71.
  16. Chen L, Wang X, Mei H, et al. Apoptosis and expression of PCNA in superficial transitional cell bladder cancer as related to recurrence. Zhonghua Wai Ke Za Zhi 1998; 36: 484-6.
  17. Korkolopoulo P, Christodoulou P, Kapralos P, et al. The role of p53, MDM2 and c-erb B2 oncoproteins, epidermal growth factor receptor and proliferation markers in prognosis of urinary bladder cancer. Pathol Res Pract 1997; 193: 767-75.
  18. Kuezyk MA, Serth J, Bokemeyer C, et al. Value of the proliferation status(PCNA) and p53 immunohistochelistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder. Urologe A 1995; 34: 146-52.
  19. Hattori K, Uchida K, Akaza H, et al. Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma. Br J Urol 1995; 75: 162-6.
  20. Y Nagase, N Moriyama, S Kurimoto, et al. Histochemical expression of proliferating cell nuclear antigen (PCNA) for preand post chemotherapeutic bladder cancer. Nihon HinyÅkika Gakkai zasshi 1995; 86: 985-90.
  21. Compérat E, Camparo P, Haus R, et al. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. European Society of Pathology 2006; 448: 319-324.
  22. Matsumoto M, Ohtsuki Y, Ochii K, et al. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep 2004; 12: 967-71.
  23. Wu TT, Chen JH, Lee YH, Huang JK. The role of BCL-2, p53 and KI-76 index in predicting tumor recurrrence for low grade superficial transitional cell bladder carcima. The Journal of Urology 2000; 163: 758-760.
  24. Fontana D, Bellina M, Gubetta L, et al. Monoclonal antibody Ki- 67 in the study of the proliferative activity of bladder carcinoma. J Urol 1992; 148: 1149-51.
  25. Moch H, Sauter G, Mihatsch MJ, et al. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 1994; 25: 1346-51.
  26. [26] Lee SE, Chow NH, Chi YC, et al. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 1994; 14: 1317-24.
  27. Carpenter CD, Ingraham HA, Cochet C, et al. Structural analysis of the transmembrane domain of the epidermal growth factor receptor. J Biol Chem 1991; 266: 5750-5.
  28. Wright C, Thomas D, Mellon K, et al. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index. Br J Urol 1995; 75: 173- 9.
  29. Asamoto M, Hasegawa R, Masuko T, et al. Immunohistochemical analysis of c-erbB-2 oncogene product and epidermal growth factor receptor expression in human urinary bladder carcinomas. Acta Pathol Jpn 1990; 40: 322-6.
  30. Baretton GB, Diebold J, Christoforis G, et al. Apoptosis and immunohistochemical bcl2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 1996; 77: 255-264.
  31. J. Diebold et al., "BCL-2 EXPRESSION, P53 ACCUMULATION, AND APOPTOSIS IN OVARIAN CARCINOMAS", Am J Clin Pathol 1996; 105: 341-349.
  32. Nakopoulou L, Vourlakou C, Zervas A, et al. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998; 29: 146-54.
  33. Vollmer RT, Humphrey PA, Swanson PE, et al. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MiB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998; 82: 715-723.
  34. Li B, Kanamaru H, Noriki S, et al. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urol Res 1998; 26: 235-41.
  35. Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of EGFR in invasive transitional cell carcinoma of the urinary bladder.A multivariate survival analysis. Am J Clin Pathol 1994 ; 101: 166- 76.
  36. Sánchez-Fernández de Sevilla MC, Morell-Quadreny L, Gil- Salom M, et al. Behavior of epithelial differentiation antigens (carcinoembryonic antigen, epithelial membrane antigen, keratin and cytokeratin) in transitional cell carcinomas of the bladder. Urol Int 1992; 48: 14-9.
  37. Jautzke G, Altenaehr E. Immunohistochemical demonstration of carcinoembryonic antigen (CEA) and its correlation with grading and staging on tissue sections of urinary bladder carcinomas. Cancer 1982; 50: 2052-6.